摘要
通过病毒在细胞质主动转运和抵制细胞的制约因子和先天免疫反应的机制,病毒已经进化到穿越细胞障碍和进入到细胞核。病毒源载体系统利用病毒的能力把遗传信息输送入细胞,基于HIV-1的HIV慢病毒载体的发现到现在已超过三十年,它已成为需要转基因的基因组插入的生物医学研究和基因治疗的工具。现在,慢病毒基因传递到干细胞、免疫系统细胞包括T细胞、肝细胞、和许多其他与治疗相关的细胞类型的有效性是公认的。伴随着核酸,HIV-1病毒体携带对感染的早期步骤是必不可少的酶工具。这种包装酶甚至是非病毒源的蛋白质的能力,揭示了利用HIV-1入侵细胞的新途径。基于早期的已表明包装外源蛋白到病毒颗粒作为Gag和GagPol多肽部分的研究结果,我们已经建立了为传递DNA转座酶和设计的核酸酶的慢病毒蛋白转运。这种传递基因组工程蛋白质的策略有利于在很短的时间内的达到高的酶活性,并可能会提高基因组编辑的安全性。利用慢病毒载体的全部潜能,掺合外源蛋白,可以结合DNA转座因子或结合“一体化”慢病毒载体的同源性定向修复的供体序列。在这里,我们简要地描述了可能会影响细胞内的病毒基因和蛋白传递的限制因素,回顾当前慢病毒颗粒作为基因工程工具包的载体的状态。
关键词: 蛋白转导,锌指核酸酶,DNA转座酶,基因治疗,慢病毒载体。
Current Gene Therapy
Title:Lentiviral Delivery of Proteins for Genome Engineering
Volume: 16 Issue: 3
Author(s): Yujia Cai, Jacob Giehm Mikkelsen
Affiliation:
关键词: 蛋白转导,锌指核酸酶,DNA转座酶,基因治疗,慢病毒载体。
摘要: Viruses have evolved to traverse cellular barriers and travel to the nucleus by mechanisms that involve active transport through the cytoplasm and viral quirks to resist cellular restriction factors and innate immune responses. Virus-derived vector systems exploit the capacity of viruses to ferry genetic information into cells, and now - more than three decades after the discovery of HIV - lentiviral vectors based on HIV-1 have become instrumental in biomedical research and gene therapies that require genomic insertion of transgenes. By now, the efficacy of lentiviral gene delivery to stem cells, cells of the immune system including T cells, hepatic cells, and many other therapeutically relevant cell types is well established. Along with nucleic acids, HIV-1 virions carry the enzymatic tools that are essential for early steps of infection. Such capacity to package enzymes, even proteins of nonviral origin, has unveiled new ways of exploiting cellular intrusion of HIV-1. Based on early findings demonstrating the packaging of heterologous proteins into virus particles as part of the Gag and GagPol polypeptides, we have established lentiviral protein transduction for delivery of DNA transposases and designer nucleases. This strategy for delivering genome-engineering proteins facilitates high enzymatic activity within a short time frame and may potentially improve the safety of genome editing. Exploiting the full potential of lentiviral vectors, incorporation of foreign protein can be combined with the delivery of DNA transposons or a donor sequence for homology-directed repair in so-called ‘all-in-one’ lentiviral vectors. Here, we briefly describe intracellular restrictions that may affect lentiviral gene and protein delivery and review the current status of lentiviral particles as carriers of tool kits for genome engineering.
Export Options
About this article
Cite this article as:
Yujia Cai, Jacob Giehm Mikkelsen , Lentiviral Delivery of Proteins for Genome Engineering, Current Gene Therapy 2016; 16 (3) . https://dx.doi.org/10.2174/1566523216666160527143702
DOI https://dx.doi.org/10.2174/1566523216666160527143702 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry A New Antitumor Agent, (3-chloro-7-methoxyfuro[2,3-b]-quinolin-4-yl)-(4-methoxyphenyl) amine, Loaded in Solid Lipid Nanoparticles: Characterization and Pharmacokinetics
Current Nanoscience Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Recent Patents on Anti-Cancer Drug Discovery Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Inducing Synthetic Lethality using PARP Inhibitors
Current Clinical Pharmacology Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Urate Transport: Regulators of Serum Urate Levels in Humans
Current Rheumatology Reviews The Epidermis as a Model for Tissue Engineering
Current Tissue Engineering (Discontinued) Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Current Drug Targets